QSAM Biosciences (OTCQB: QSAM) is developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of bone cancer and related diseases and conditions. The company today announced that it was invited to provide updates on its clinical trial evaluating CycloSam for the treatment of metastatic bone cancer at the upcoming Emerging Growth Conference. Scheduled to participate at 2:50 p.m. Eastern Time on Wednesday, March 22, 2023, QSAM’s CEO and other executive officers will provide a presentation and potentially open the floor for questions. Interested parties should visit https://ibn.fm/UrQ6g to register for and access the webcast.
To view the full press release, visit https://ibn.fm/1n6N5
About QSAM Biosciences Inc.
QSAM Biosciences is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM’s initial technology, CycloSam(R) (Samarium-153 DOTMP), is a clinical-stage bone-targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed the FDA-approved Quadramet(R) (Samarium-153 EDTMP) radiopharmaceutical product, which is indicated for pain palliation. QSAM is led by an experienced executive team and board of directors that have completed numerous FDA approvals and multiple successful biotech exits. For more information, visit the company’s website at https://QSAMBio.com.
NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
